MetaVia announced positive interim Phase 1 results for DA-1726, a dual GLP-1 and glucagon receptor agonist, showing a 68% placebo-adjusted liver fat reduction and 13.5% weight loss after 16 weeks in obese adults. The drug also improved HbA1c levels and reduced visceral and subcutaneous fat while preserving lean muscle. These results support advancing DA-1726 into Phase 2 trials targeting metabolic and alcohol-associated liver diseases, with a 48-week study planned for late 2027. No new serious gastrointestinal side effects were reported after week 9, indicating good tolerability.
MetaVia's DA-1726 interim data shows a 68% liver fat reduction. For readers following health stocks, here is Pluang's market snapshot as of Nov 05, 2026 19:42 WIB: out of 150 US health stocks, 87 rose and 56 fell. Notable moves include IOVA at USD 9.13 (+4.94%), ALNY at USD 168.00 (+4.30%), and OSCR at USD 33.80 (-3.95%).
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
